Epalinges, Switzerland, March 5, 2026 – Novigenix SA, a leader in immunotranscriptomic diagnostics, today announced the formal spin-out and launch of Novigenix AI, a new precision medicine company dedicated to transforming therapy development through AI-powered immune intelligence. A Strategic Separation to Unlock Two High-Growth Markets The new AI spin-out separates Novigenix's colorectal cancer (CRC)
Lausanne, Switzerland, March 31, 2025 – Novigenix AI, a leader in AI-driven precision liquid biopsy solutions, has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence. The BRECISE consortium was launched
Lausanne, Switzerland, March 11, 2025 - Novigenix AI, a leader in AI-driven healthcare solutions, has published a groundbreaking study showcasing the predictive power of its LITOSeek™ platform for immunotherapy response in metastatic urothelial cancer. The study titled, “Multimodal Integration of Blood RNA and ctDNA Reflects Response to Immunotherapy in Metastatic Urothelial Cancer” [link], has
Lausanne, Switzerland, November 25, 2024 – Novigenix AI, a leader in AI-driven healthcare solutions, has published a new study marking a significant milestone in advancing early colorectal cancer (CRC) detection through innovative immune system profiling. The groundbreaking research, “Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression,” [link] has been published in the Journal for Immunotherapy of
By Pedro Romero, Chief Medical & Scientific Officer of Novigenix AI - Identifying markers in body fluids via liquid biopsy holds great promise for detecting diseases (such as cancer) at early stages, following disease progression and population heterogeneity, and, importantly, predicting a response to therapy with minimal patient inconvenience. Liquid biopsy relies on easy
Lausanne, Switzerland, September 24, 2024 – Groundbreaking funding promises to revolutionize care for patients with advanced prostate cancer by addressing treatment resistance through innovative liquid biopsy technology. Novigenix AI, a leader in AI-driven healthcare solutions, has today announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling
Lausanne, Switzerland, September 12, 2024 – Novigenix AI, an innovator in precision medicine and liquid biopsy technologies, will showcase its multimodal approach at the European Society for Medical Oncology (ESMO) 2024 conference. This is poised to revolutionize the landscape of oncology treatment and drug development. The new approach combines advanced immune profiling with cell-free DNA (cfDNA)
Geneva, September 11, 2024 - Novigenix AI, a leader in AI-driven healthcare solutions, successfully achieved ISO 13485:2016 certification, passing the Stage II audit with zero non-conformities. This milestone underscores Novigenix AI's unwavering commitment to the highest standards of quality in providing solutions for the biopharma industry. ISO 13485:2016 is an internationally recognized standard for quality
Lausanne, May 29, 2024 – Novigenix AI, a leader in AI-driven healthcare solutions, has been awarded the prestigious recognition of 'Best 2024 Technology Innovation' in oncology by the MATWIN Board, the premier European convention dedicated to innovation in cancer treatment. This recognition highlights Novigenix AI's groundbreaking contributions to personalized cancer care and its commitment
Recent research in the New England Journal of Medicine highlights significant advances in colorectal cancer (CRC) screening. Novigenix AI leads this innovation with our unique approach that combines liquid biopsy, AI, and RNA analysis, promising a transformative impact on early cancer detection. Colorectal cancer is a major global health concern, projected to rise by